Chemo-immunotherapy without anthracyclines for early triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks back at the outcomes of people with early triple-negative breast cancer who had chemo-immunotherapy without anthracyclines before surgery. It aims to see how well this drug combination worked, which may help guide future treatment choices for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have localized (not spread) triple-negative breast cancer.
- You received chemotherapy plus immunotherapy before your surgery, without an anthracycline drug.
- You have already had surgery and have a pathology report available.
- You have not received any anthracycline-based treatment cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial looks at whether adding immunotherapy to chemotherapy before surgery helps people with triple-negative breast cancer. It compares different treatment approaches to see which works better.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests a combination of chemotherapy and two immunotherapy drugs given before surgery for women and men with triple-negative breast cancer. The goal is to see if this approach helps shrink or eliminate the tumor before surgery.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.